Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Pramlintide

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

AstraZeneca · Phase 2 · Completed · Enrollment 636

NCT00673387

ArmPopulationDoseWeeksEstimandWeight change
Placebo-P + Placebo-MObesity or overweightn/rn/rn/rn/r
Pramlintide 360 mcg + Placebo-MObesity or overweight360 mcgn/rn/rn/r
Placebo-P + Metreleptin 5.0 mgObesity or overweight5.0 mgn/rn/rn/r
Pramlintide 180 mcg + Metreleptin 2.5 mgObesity or overweight2.5 mgn/rn/rn/r
Pramlintide 180 mcg + Metreleptin 5.0 mgObesity or overweight5.0 mgn/rn/rn/r
Pramlintide 360 mcg + Metreleptin 1.25 mgObesity or overweight1.25 mgn/rn/rn/r
Pramlintide 360 mcg + Metreleptin 2.5 mgObesity or overweight2.5 mgn/rn/rn/r
Pramlintide 360 mcg + Metreleptin 5.0 mgObesity or overweight5.0 mgn/rn/rn/r